Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch for sugar: could a CGM get people moving and stop diabetes before it starts?

NCT ID NCT07455435

Prevention Sponsor: University of Hartford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether wearing a continuous glucose monitor (CGM) can motivate people with prediabetes to be more physically active. Fifty adults with prediabetes will wear a CGM for 20 days and receive education on their blood sugar readings. The goal is to see if seeing real-time glucose data encourages more steps and helps stabilize blood sugar, potentially preventing type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitor (CGM) and physical activity education
What this could lead to
If it works, this could point toward a simple, wearable-based strategy to help people with prediabetes increase physical activity and lower their risk of developing type 2 diabetes.
What could go wrong
This is a small, early-stage study with only 50 participants and no control group, so results may not be generalizable. The intervention is short-term (20 days), so any benefits might not last.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults aged 18 years or older Prediabetes confirmed by the recent lab tests (within three month). If not available, it will be confirmed at lab Body mass index (BMI) \>= 25 kg/m2 Ability to provide informed consent Ownership of a smartphone compatible with Dexcom G6 application Willing and able to comply with study procedures for 20 days Exclusion Criteria: Diabetes and Glycemic Management: * Diagnosed type 1 or type 2 diabetes mellitus * Current use of glucose-lowering medications (metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, insulin, etc.) * HbA1c \>= 6.5% or fasting plasma glucose \>= 126 mg/dL Cardiovascular Conditions: * History of cardiovascular disease (myocardial infarction, stroke, heart failure, coronary artery disease) * Peripheral artery disease * Uncontrolled hypertension (systolic BP \> 160 mmHg or diastolic BP \> 100 mmHg) * Raynaud phenomenon or other conditions affecting peripheral vascular assessment * Atrial fibrillation or other arrhythmias affecting pulse wave velocity measurement Medications Affecting Vascular Function: * Current use of vasoactive medications (nitrates, phosphodiesterase inhibitors) * Recent changes (\< 4 weeks) in antihypertensive medications * Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) * Systemic corticosteroid use Physical Activity Limitations: * Physical disability or musculoskeletal condition preventing normal ambulation * Use of mobility aids (wheelchair, walker, cane) * Medical advice to limit physical activity Other Exclusions: * Pregnancy or lactation * Active cancer or cancer treatment within the past 5 years (excluding non-melanoma skin cancer) * Chronic kidney disease (eGFR \< 60 mL/min/1.73m2) * Liver disease (ALT or AST \> 3x upper limit of normal) * Thyroid disease (unless stable on treatment for \> 3 months) * Current participation in a weight loss program or clinical trial * Skin conditions preventing CGM sensor placement * Known allergy to CGM adhesive * Shift work or irregular sleep schedule (may affect CGM patterns) * Planned travel during study period that would interfere with study visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.